Engene Holdings INC Form 4 insider transactions

Director Philip Astley-Sparke was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

Director Gerald A. Brunk was granted 31,000 stock options in enGene Therapeutics Inc. as part of standard equity compensation.

Director Richard M. Glickman was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

Interim Chief Medical Officer William Grossman was granted 231,000 stock options by enGene Therapeutics Inc. on June 16, 2026.

Director Paul Hastings was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity incentive.

Director Michael Heffernan was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

Director Wouter Joustra was granted 31,000 stock options in enGene Therapeutics Inc. as part of standard equity compensation.

Director Lota S. Zoth was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

enGene Holdings Inc.'s Chief Scientific Officer, Anthony T. Cheung, was granted 195,000 stock options with an exercise price of $9.53, vesting over 48 months.

enGene Holdings Inc.'s Chief Legal Officer, Lee Giguere, was granted 195,000 stock options with an exercise price of $9.53.

enGene Holdings Inc. granted 195,000 stock options to Chief Strategy & Operations Officer Alexander Julian Nichols.

enGene Holdings Inc.'s Chief Financial Officer, D. Ryan Daws, acquired 220,000 stock options with an exercise price of $9.53, vesting over 48 months.

enGene Holdings Inc.'s CEO and President, Ronald Harold Wilfred Cooper, was granted 801,000 stock options with an exercise price of $9.53, vesting over 48 months.

enGene Holdings Inc.'s Chief Technology Officer, Joan Connolly, was granted 195,000 stock options with an exercise price of $9.53, vesting over 48 months.

enGene Holdings Inc. granted its Chief Regulatory Officer, Matthew Ross Boyd, 195,000 stock options with an exercise price of $9.53, vesting over 48 months.

enGene Holdings Inc.'s Chief Development Officer, Jill Buck, was granted 195,000 stock options with an exercise price of $9.53.

enGene Holdings Inc. Chief Medical Officer Hussein Sweiti received a grant of 600,000 non-qualified stock options with a $6.83 exercise price.

enGene Holdings Inc. Chief Regulatory Officer Matthew Ross Boyd was granted 100,000 stock options with an exercise price of $3.83, vesting over 48 months.

enGene Holdings Inc. Director Philip Astley-Sparke was granted 45,000 stock options with an exercise price of $3.83, vesting over three years.

enGene Holdings Inc. Director Michael Thomas Heffernan was granted 45,000 stock options with an exercise price of $3.83, vesting over three years following his appointment to the Board.

enGene Holdings Inc. Director William Grossman was granted 45,000 stock options with an exercise price of $3.83, vesting over three years.

enGene Holdings Inc. has granted its Chief Development Officer, Jill Buck, 100,000 stock options with an exercise price of $3.83, effective July 8, 2025.

enGene Holdings Inc. Director Lota S. Zoth was granted 22,500 stock options at an exercise price of $3.31, aligning her interests with the company's long-term performance.

enGene Holdings Inc. has granted 400,000 non-qualified stock options to its Chief Global Communications Officer, Amy Pott, as an inducement award.

enGene Holdings Inc. Director Wouter Joustra was granted 22,500 stock options with an exercise price of $3.31, vesting by June 2026.

Paul J. Hastings, a Director at enGene Holdings Inc., was granted 22,500 stock options with an exercise price of $3.31, vesting over the next year or by the 2026 Annual Meeting of Shareholders.

enGene Holdings Inc. Director and 10% Owner Richard M. Glickman reported the acquisition of 22,500 stock options with an exercise price of $3.31, which will fully vest by the earlier of June 10, 2026, or the 2026 Annual Meeting of Shareholders.

enGene Holdings Inc. Director and 10% Owner Gerald A. Brunk was granted 22,500 stock options with an exercise price of $3.31, vesting over the next year or by the 2026 Annual Meeting of Shareholders.

enGene Holdings Inc. Director Jasper Bos was granted 22,500 stock options with an exercise price of $3.31, aligning his interests with shareholders.

Raj Som Pruthi, Chief Medical Officer of enGene Holdings Inc., was granted stock options for 280,000 common shares on January 29, 2025.